Skip to main content

March 2016, Vol 9, Seventh Annual Payers' Guide

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas

Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder

Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

ProAir RespiClick (Albuterol Sulfate): First Breath-Actuated Inhaler Approved for the Treatment or Prevention of Bronchospasm

Lisa A. Raedler, PhD, RPh

Opdivo (Nivolumab), a PD-1 Inhibitor, Receives New Indications for Melanoma, NSCLC, and Renal-Cell Carcinoma

Lisa A. Raedler, PhD, RPh

Odomzo (Sonidegib), a Hedgehog Pathway Inhibitor, FDA Approved for the Treatment of Patients with Locally Advanced Basal-Cell Carcinoma

Iressa (Gefitinib), Oral Tyrosine Kinase Inhibitor, Approved for First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutation

Cyramza (Ramucirumab) Receives New FDA Indication for Second-Line Treatment of Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh

Cotellic (Cobimetinib) FDA Approved as Part of a Combination for Patients with Advanced Melanoma and a BRAF Mutation

Page 1 of 5
Results 1 - 10 of 43